Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin + TMP/SMZ for Severe PCP in Non-HIV Patients
NCT03978559Phase 4Unknown
- Sponsor
- Bin Du
- Start
- Aug 2019
- Primary completion
- Jun 2022
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of caspofungin in pneumocystis pneumonia (PCP) (2 arms), sponsored by Bin Du. Primary endpoint: Mortality to day 28. Status: unknown.
02
Drugs
caspofungin
03
Conditions
pneumocystis pneumonia (PCP)
Beyond the preview
Go deeper on NCT03978559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978559.